Crossmark

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

Crossref DOI link: https://doi.org/10.1007/s13555-022-00861-4

Published Online: 2022-12-13

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gisondi, Paolo

Gottlieb, Alice B.

Elewski, Boni

Augustin, Matthias

McBride, Sandy

Tsai, Tsen-Fang

de la Loge, Christine

Fierens, Frederik

López Pinto, José M.

Tilt, Nicola

Lebwohl, Mark http://orcid.org/0000-0002-4705-5303
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02326298 at ClinicalTrials.gov

Documents that mention this clinical trial

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)
https://doi.org/10.1007/s13555-022-00861-4

nct02326272 at ClinicalTrials.gov

Documents that mention this clinical trial

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)
https://doi.org/10.1007/s13555-022-00861-4
Funding

Funding for this research was provided by:

Dermira

UCB Pharma
License Information

Text and Data Mining valid from 2022-12-13

Version of Record valid from 2022-12-13
More Information

Article History

Received: 5 October 2022

Accepted: 9 November 2022

First Online: 13 December 2022

Change Date: 25 June 2024

Change Type: Update

Change Details: Volume and pages updated in header

Change Date: 30 May 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13555-023-00934-y

Updates are available Correction dated 2023-05-30

Click to view Correction: https://doi.org/10.1007/s13555-023-00934-y